-
Romanian parliament votes to oust pro-EU PM
-
Ethiopia and Sudan accuse each other of attacks
-
Injured Mbappe faces backlash over Sardinia trip before Clasico
-
Vodafone to take full ownership of UK mobile operator
-
Sabalenka ready to boycott Grand Slams over prize money
-
US forces ready to resume combat operations against Iran if ordered
-
Boko Haram attack on Chad army base kills at least 24: military, local officials
-
US trade gap widens in March as AI spending boosts imports
-
US threatens 'devastating' response to any Iran attack on shipping
-
Murphy warns snooker hopefuls to 'work harder' to match Chinese stars
-
Race to find port for hantavirus-stricken cruise ship
-
Romanian pro-EU PM loses no-confidence motion
-
Stocks diverge as traders eye US-Iran ceasefire
-
Edin Terzic to become Athletic Bilbao coach next season
-
Borthwick backed by RFU to take England to 2027 Rugby World Cup
-
EU hails 'leap forward' in ties with Russia's ally Armenia
-
German car-ramming suspect had mental health problems: reports
-
Pyongyang calling: North Korea shows off own-brand phones
-
Iran warns 'not even started' in Hormuz
-
World body in dark over allegations against China badminton chief
-
Asian stocks drop amid fears over US-Iran ceasefire
-
China fireworks factory explosion kills 26, injures 61
-
China hails 'our era' as Wu Yize's world snooker triumph goes viral
-
Ex-model accuses French scout of grooming her for Epstein
-
Timberwolves eclipse Spurs as Knicks rout Sixers
-
Taiwan leader says island has 'right to engage with the world'
-
Yoko says oh no to 'John Lemon' beer
-
Bayern's Kompany promises repeat fireworks in PSG Champions League semi
-
A coaching great? Luis Enrique has PSG on brink of another Champions League final
-
Top five moments from the Met Gala
-
Brunson leads Knicks in rout of Sixers
-
Retiring great Sophie Devine wants New Zealand back playing Tests
-
Stocks sink amid fears over US-Iran ceasefire
-
G7 trade ministers set to meet but not discuss latest US tariff threat
-
Sherlock Holmes fans recreate fateful duel at Swiss falls
-
Premier League losses soar for clubs locked in 'arms race'
-
'Spreading like wildfire': Fiji grapples with soaring HIV cases
-
For Israel's Circassians, food and language sustain an ancient heritage
-
'Super El Nino' raises fears for Asia reeling from Middle East conflict
-
Trouble in paradise: Colombia tourist jewel plagued by violence
-
Death toll in Brazil small plane crash rises to three
-
Pulitzers honor damning coverage of Trump and his policies
-
Digi Power X Signs AI Colocation Agreement with Leading AI Compute Company for 40 MW Data Center in Columbiana, Alabama
-
LA fire suspect had grudge against wealthy: prosecutors
-
US-Iran ceasefire on brink as UAE reports attacks
-
Stars shine at Met Gala, fashion's biggest night
-
Birthday girl, 10, among dead in Colombia monster truck crash
-
Blake Lively, Justin Baldoni agree to end lengthy legal battle
-
Dolly Parton cancels Las Vegas shows over health concerns
-
Wu Yize: China's 'priest' who conquered the snooker world
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
K.Thomson--BTB